Trial reportBMC gastroenterology2014
Efficacy of transoral fundoplication for treatment of chronic gastroesophageal reflux disease incompletely controlled with high-dose proton-pump inhibitors therapy: a randomized, multicenter, open label, crossover study.
Trial report in BMC gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis.Gastrointestinal endoscopy · 2023Pooled it
- Efficacy of transoral incisionless fundoplication (TIF) for the treatment of GERD: a systematic review with meta-analysis.Surgical endoscopy · 2017Pooled it
- Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults.The Cochrane database of systematic reviews · 2015Pooled it
- The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.Surgical innovation · 2018Trial
- Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm.Surgical endoscopy · 2017Trial
- Article
- The role of transoral incisionless fundoplication (TIF) in the management of gastroesophageal reflux disease (GERD) following peroral endoscopic myotomy (POEM): A pilot, prospective, patient-driven study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2024Article
- Transoral incisionless fundoplication for recurrent symptoms after laparoscopic fundoplication.Surgical endoscopy · 2023Article
- Recent Advances in the Endoscopic Management of Gastro-esophageal Reflux Disorder: A Review of Literature.Cureus · 2022Review
- Collaboration between GI surgery & Gastroenterology improves understanding of the optimal antireflux valve-the omega flap valve.Surgical endoscopy · 2021Article
- Efficacy and patient satisfaction of single-session transoral incisionless fundoplication and laparoscopic hernia repair.Surgical endoscopy · 2021Article
- Mind the Gap: Current Treatment Alternatives for GERD Patients Failing Medical Treatment and Not Ready for a Fundoplication.Surgical laparoscopy, endoscopy & percutaneous techniques · 2020Review
- Management of Gastroesophageal Reflux Disease in the Elderly Patient.Drugs & aging · 2019Review
- Current Trends in the Management of Gastroesophageal Reflux Disease.Gut and liver · 2018Review
- Endoscopic Management of Gastroesophageal Reflux Disease: Revisited.Clinical endoscopy · 2016Review
- Endoscopic Options for Gastroesophageal Reflux: Where Are We Now and What Does the Future Hold?Current gastroenterology reports · 2016Review
- Transoral incisionless fundoplication: current status.Current opinion in gastroenterology · 2016Review
- Transoral Incisionless Fundoplication for Refractory Gastroesophageal Reflux Disease: Where Do We Stand?Clinical endoscopy · 2016Review
- Randomized Controlled Trial of Transoral Incisionless Fundoplication Vs. Proton Pump Inhibitors for Treatment of Gastroesophageal Reflux Disease.The American journal of gastroenterology · 2015Article
- pH Scores in Hiatal Repair with Transoral Incisionless Fundoplication.JSLS : Journal of the Society of Laparoendoscopic SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this randomized, crossover study was to determine if transoral fundoplication (TF) could further improve clinical outcomes in partial responders to high-dose (HD) proton-pump inhibitor (PPI) therapy and to evaluate durability of TF.
methodsIn seven United States centers, patients with hiatal hernia ≤ 2 cm and abnormal esophageal acid exposure (EAE) were randomized to TF (n = 40) or HD PPIs (n = 23) group. At 6-month follow-up, PPI patients underwent crossover. We assessed clinical outcomes 6-month post TF in crossover patients (COP), as compared to 6-month of HD PPI therapy, and 12-month outcomes in patients initially randomized to TF. The primary outcome was symptom control evaluated by Reflux Disease Questionnaire and Reflux Symptom Index. Secondary outcomes included healing of esophagitis, normalization of EAE and PPI use after TF. We analyzed 21 COP and 39 TF patients. McNemar's test or Fisher exact test was used to compare proportions.
resultsOf 63 randomized patients, 3 were lost to follow-up, leaving 39 TF and 21 COP for analyses. In the COP, TF further improved control of regurgitation and of atypical symptoms achieved after six months of HD PPIs. Of 20 patients with GERD symptoms after six months of high-dose PPI therapy, 65% (13/20) reported global elimination of troublesome regurgitation and atypical symptoms post TF off PPIs; 67% (6/9) reported no troublesome regurgitation. Esophagitis further healed in 75% (6/8) of patients. Seventy-one percent of COP patients were off PPIs six months following TF. Normalization of EAE decreased from 52% after HD PPIs (on PPIs) to 33% after TF (off PPIs), p =0.388. In the original TF group, 12-month post TF, 77% of patients achieved complete symptom control, 82% ceased PPI therapy, 100% healed esophagitis and 45% normalized EAE.
conclusionsThe results of this study indicate that in patients with incomplete symptom control on high-dose PPI therapy TF may provide further elimination of symptoms and esophagitis healing. In the original TF group, the clinical outcomes of TF remained stable between 6- and 12-month follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.